Skip to main content

Psoriasis

ALN
Findings from a recent analysis of phase 3 AMAGINE-2 and AMAGINE-3 trials showed greater benefit with brodalumab compared with ustekinumab for patients with psoriasis.
The Dermatologist
A recent study demonstrated the safety and long-term effectiveness of bimekizumab, with participants maintaining high PASI scores through 60 weeks of treatment.
The Dermatologist
Psoriasis is associated with many comorbid conditions. In an interview with The Dermatologist, Ronald Prussick, MD, discusses the latest research on these comorbidities, evidence on lifestyle and treatment options that could potentially prevent or manage both psoriasis and comorbid conditions, and the importance of screening and aggressively treating psoriatic arthritis.
ALN
In a recent study, researchers investigated whether dose reduction of biologics was noninferior to usual care among patients with well-controlled plaque psoriasis.
The Dermatologist
Results from a small retrospective study suggest adding apremilast to biologic therapy may be a safe and effective option for biologic fatigue among patients with psoriasis.
Back to Top